Abstract
Lung cancer is one of the leading cancer malignancies, with a five-year survival rate of only ∼15%. We have developed a lentiviral-vector-mediated mouse model, which enables generation of non-small-cell lung cancer from less than 100 alveolar epithelial cells, and investigated the role of IKK2 and NF-κB in lung-cancer development. IKK2 depletion in tumour cells significantly attenuated tumour proliferation and significantly prolonged mouse survival. We identified Timp1, one of the NF-κB target genes, as a key mediator for tumour growth. Activation of the Erk signalling pathway and cell proliferation requires Timp-1 and its receptor CD63. Knockdown of either Ikbkb or Timp1 by short hairpin RNAs reduced tumour growth in both xenograft and lentiviral models. Our results thus suggest the possible application of IKK2 and Timp-1 inhibitors in treating lung cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
£139.00 per year
only £11.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Accession codes
Change history
26 February 2015
The version of this Article originally published should have acknowledged that this work was also supported by NIH grant number CA158191. This has been corrected in all online versions of the Article.
References
Karin, M. Nuclear factor- κB in cancer development and progression. Nature 441, 431–436 (2006).
Barbie, D. A. et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462, 108–112 (2009).
Basseres, D. S., Ebbs, A., Levantini, E. & Baldwin, A. S. Requirement of the NF-κB subunit p65/RelA for K-Ras-induced lung tumorigenesis. Cancer Res. 70, 3537–3546 (2010).
Meylan, E. et al. Requirement for NF-κB signalling in a mouse model of lung adenocarcinoma. Nature 462, 104–107 (2009).
Takahashi, H., Ogata, H., Nishigaki, R., Broide, D. H. & Karin, M. Tobacco smoke promotes lung tumorigenesis by triggering IKK β- and JNK1-dependent inflammation. Cancer Cell 17, 89–97 (2010).
Bivona, T. G. et al. FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR. Nature 471, 523–526 (2011).
Karin, M., Yamamoto, Y. & Wang, Q. M. The IKK NF-κB system: a treasure trove for drug development. Nat. Rev. Drug Discov. 3, 17–26 (2004).
Baud, V. & Karin, M. Is NF-κB a good target for cancer therapy? Hopes and pitfalls. Nat. Rev. Drug Discov. 8, 33–40 (2009).
Li, Q. & Verma, I. M. NF-κB regulation in the immune system. Nat. Rev. Immunol. 2, 725–734 (2002).
Herbst, R. S., Heymach, J. V. & Lippman, S. M. Lung cancer. New Engl. J. Med. 359, 1367–1380 (2008).
Ding, L. et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455, 1069–1075 (2008).
Frese, K. K. & Tuveson, D. A. Maximizing mouse cancer models. Nat. Rev. Cancer 7, 654–658 (2007).
Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).
Sutherland, K. D. & Berns, A. Cell of origin of lung cancer. Mol. Oncol. 4, 397–403 (2010).
Kim, C. F. et al. Mouse models of human non-small-cell lung cancer: raising the bar. Cold Spring Harb. Symp. Quant. Biol. 70, 241–250 (2005).
Meuwissen, R. Mouse models for human lung cancer. Genes Dev. 19, 643–664 (2005).
Kafri, T., Blomer, U., Peterson, D. A., Gage, F. H. & Verma, I. M. Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. Nat. Genet. 17, 314–317 (1997).
Jackson, E. L. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 15, 3243–3248 (2001).
Aljada, I. S. et al. Upregulation of the tissue inhibitor of metalloproteinase-1 protein is associated with progression of human non-small-cell lung cancer. J. Clin. Oncol. 22, 3218–3229 (2004).
Fong, K. M., Kida, Y., Zimmerman, P. V. & Smith, P. J. TIMP1 and adverse prognosis in non-small cell lung cancer. Clin. Cancer Res. 2, 1369–1372 (1996).
Fleming, R. E. et al. Carbonic anhydrase II expression in rat type II pneumocytes. Am. J. Respir. Cell. Mol. Biol. 10, 499–505 (1994).
Jackson, E. L. The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res. 65, 10280–10288 (2005).
Rekhtman, N. Neuroendocrine tumors of the lung: an update. Arch. Pathol. Lab. Med. 134, 1628–1638 (2010).
Feldser, D. M. et al. Stage-specific sensitivity to p53 restoration during lung cancer progression. Nature 468, 572–575 (2010).
Junttila, M. R. et al. Selective activation of p53-mediated tumour suppression in high-grade tumours. Nature 468, 567–571 (2010).
Tang, X. et al. Nuclear factor- κB (NF- κB) is frequently expressed in lung cancer and preneoplastic lesions. Cancer 107, 2637–2646 (2006).
Karin, M. & Ben-Neriah, Y. Phosphorylation meets ubiquitination: the control of NF-κB activity. Annu. Rev. Immunol. 18, 621–663 (2000).
Janssens, S. & Tschopp, J. Signals from within: the DNA-damage-induced NF-κB response. Cell Death Differ. 13, 773–784 (2006).
Mantovani, A., Allavena, P., Sica, A. & Balkwill, F. Cancer-related inflammation. Nature 454, 436–444 (2008).
Thomas, P., Khokha, R., Shepherd, F. A., Feld, R. & Tsao, M. S. Differential expression of matrix metalloproteinases and their inhibitors in non-small cell lung cancer. J. Pathol. 190, 150–156 (2000).
Stetler-Stevenson, W. G. Tissue inhibitors of metalloproteinases in cell signaling: metalloproteinase-independent biological activities. Sci. Signal. 1, re6 (2008).
Wilczynska, K. M. et al. A novel mechanism of tissue inhibitor of metalloproteinases-1 activation by interleukin-1 in primary human astrocytes. J. Biol. Chem. 281, 34955–34964 (2006).
Jiang, Y., Goldberg, I. D. & Shi, Y. E. Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 21, 2245–2252 (2002).
Jung, K. K., Liu, X. W., Chirco, R., Fridman, R. & Kim, H. R. Identification of CD63 as a tissue inhibitor of metalloproteinase-1 interacting cell surface protein. EMBO J. 25, 3934–3942 (2006).
Podolin, P. L. Attenuation of murine collagen-induced arthritis by a novel, potent, selective small molecule inhibitor of IκB kinase 2, TPCA-1 (2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide), occurs via reduction of proinflammatory cytokines and antigen-induced T cell proliferation. J. Pharmacol. Exp. Therapeut. 312, 373–381 (2004).
Birrell, M. A. et al. Iκ-B kinase-2 inhibitor blocks inflammation in human airway smooth muscle and a rat model of asthma. Am. J. Respir. Crit. Care Med. 172, 962–971 (2005).
Blasco, R. B. et al. c-Raf, but not B-Raf, is essential for development of K-ras oncogene-driven non-small cell lung carcinoma. Cancer Cell 19, 652–663 (2011).
Greten, F. R. et al. NF-κB is a negative regulator of IL-1β secretion as revealed by genetic and pharmacological inhibition of IKKβ. Cell 130, 918–931 (2007).
Nguyen, Q. et al. Different domain interactions are involved in the binding of tissue inhibitors of metalloproteinases to stromelysin-1 and gelatinase A. Biochemistry 33, 2089–2095 (1994).
Pasparakis, M. et al. TNF-mediated inflammatory skin disease in mice with epidermis-specific deletion of IKK2. Nature 417, 861–866 (2002).
Safran, M. et al. Mouse reporter strain for noninvasive bioluminescent imaging of cells that have undergone Cre-mediated recombination. Mol. Imaging 2, 297–302 (2003).
Tiscornia, G., Singer, O. & Verma, I. M. Production and purification of lentiviral vectors. Nat. Protoc. 1, 241–245 (2006).
Naka, S. et al. Activation of human CAII gene promoter by v-Src: existence of Ras-dependent and -independent pathways. Biochem. Biophys. Res. Commun. 272, 808–815 (2000).
Rankin, J. A. et al. Phenotypic and physiologic characterization of transgenic mice expressing interleukin 4 in the lung: lymphocytic and eosinophilic inflammation without airway hyperreactivity. Proc. Natl Acad. Sci. USA 93, 7821–7825 (1996).
DuPage, M., Dooley, A. L. & Jacks, T. Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat. Protocol. 4, 1064–1072 (2009).
Sweet-Cordero, A. et al. An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. Nat. Genet. 37, 48–55 (2005).
Baldi, P. & Long, A. D. A Bayesian framework for the analysis of microarray expression data: regularized t-test and statistical inferences of gene changes. Bioinformatics 17, 509–519 (2001).
Mootha, V. K. et al. PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 34, 267–273 (2003).
Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005).
Pavlidis, P. & Noble, W. S. Matrix2png: a utility for visualizing matrix data. Bioinformatics 19, 295–296 (2003).
Acknowledgements
We appreciate the generosity of M. Pasparakis for providing the IKK2fl/fl mouse, and T. Takeya and H. Nakajima for tissue-specific promoter plasmids. We thank L. Ouyang for assistance with microarray preparation. We also thank G. Pao, O. Singer, F. Liu, D. Morvinski, Q. Zhu and Y. Soda for advice on lentiviral vector designing and discussions, and G. Estepa for assistance with preparing frozen sections. N.Y. is supported by a fellowship from the Leona and Harry Helmsley Center for Nutritional Genomics (Salk Institute). I.M.V. is an American Cancer Society Professor of Molecular Biology, and holds the Irwin and Joan Jacobs Chair in Exemplary Life Science. This work was supported in part by grants from the National Institutes of Health, Leducq Foundation, Merieux Foundation, Ellison Medical Foundation, Ipsen/Biomeasure, Sanofi Aventis, Prostate Cancer Foundation, Department of Defense and the H.N. and Frances C. Berger Foundation. The project described was supported in part by grant number R37AI048034 from the National Institute of Allergy and Infectious Diseases, and Cancer Center Core Grant P30CA014195-38. This work was also supported by NIH grant number CA158191.
Author information
Authors and Affiliations
Contributions
Y.X. designed and carried out the experiments and wrote the paper. N.Y. carried out Timp-1-related experiments and microarray analysis. M.L. examined tumour samples and interpreted tumour histology. E.K. analysed the microarray data. Y.Z. and E.O. synthesized IKK2 inhibitors. R.J.S. provided mouse lines and gave advice on the project. I.M.V. supervised the project and wrote the paper.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Information
Supplementary Information (PDF 1318 kb)
Supplementary Table 1
Supplementary Information (XLSX 10 kb)
Rights and permissions
About this article
Cite this article
Xia, Y., Yeddula, N., Leblanc, M. et al. Reduced cell proliferation by IKK2 depletion in a mouse lung-cancer model. Nat Cell Biol 14, 257–265 (2012). https://doi.org/10.1038/ncb2428
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncb2428